Theravance Biopharma (NASDAQ:TBPH) Lowered to "Buy" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Theravance Biopharma from a "strong-buy" to a "buy"; across analysts the firm has two Strong Buy, two Buy and four Hold ratings, with an average rating of "Moderate Buy" and an average price target of $21.83.
• The stock opened at $16.79, trades in a 52-week range of $8.33–$21.03, and the company has a market cap of about $864.85 million with a PE ratio of 8.27.
• Insider activity: SVP Rhonda Farnum sold 31,067 shares on March 16 at an average price of $13.96; the article notes insiders own 6.9% of shares while institutional investors own roughly 99.1%.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research report issued to clients and investors on Saturday.

A number of other equities research analysts have also weighed in on TBPH. Weiss Ratings lowered shares of Theravance Biopharma from a "buy (b-)" rating to a "hold (c+)" rating in a report on Friday, April 10th. BTIG Research restated a "buy" rating and issued a $21.00 target price on shares of Theravance Biopharma in a report on Friday, March 20th. B. Riley Financial upped their target price on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a "neutral" rating in a report on Tuesday, April 7th. Zacks Research upgraded shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Thursday, March 19th. Finally, Oppenheimer lowered shares of Theravance Biopharma from an "outperform" rating to a "market perform" rating in a report on Thursday, March 5th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Theravance Biopharma has an average rating of "Moderate Buy" and an average price target of $21.83.

Theravance Biopharma Price Performance

TBPH opened at $16.79 on Friday. Theravance Biopharma has a fifty-two week low of $8.33 and a fifty-two week high of $21.03. The firm has a market capitalization of $864.85 million, a PE ratio of 8.27 and a beta of 0.19. The company's 50-day moving average is $15.94 and its 200 day moving average is $17.27.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the sale, the senior vice president owned 232,699 shares in the company, valued at approximately $3,248,478.04. This trade represents a 11.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 6.90% of the company's stock.

Institutional Investors Weigh In On Theravance Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in TBPH. Quarry LP purchased a new stake in Theravance Biopharma in the 3rd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd increased its stake in Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company's stock valued at $40,000 after buying an additional 1,411 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company's stock valued at $46,000 after buying an additional 515 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock valued at $55,000 after acquiring an additional 781 shares during the period. Finally, CIBC Private Wealth Group LLC grew its position in shares of Theravance Biopharma by 20,269.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company's stock valued at $68,000 after acquiring an additional 4,662 shares during the period. Hedge funds and other institutional investors own 99.10% of the company's stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.